RTP Mobile Logo
RTP TV: Part III — Individualizing Therapy in Non-Small Cell Lung Cancer (NSCLC)
Released July 2011

The third seminar of our eight-part online, integrated educational course explores topics relevant to the treatment of NSCLC. Originally held on June 28, 2011, part III features Drs Lucian R Chirieac, Thomas J Lynch Jr and Lecia V Sequist. (Webinar)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.


    The number of available cytotoxic chemotherapies exhibiting activity in lung cancer has increased substantially over the past several years. Of importance, recent data have demonstrated the emerging role of both biologic and cytotoxic maintenance therapy among patients with Stage IIIB/IV NSCLC experiencing initial response to standard front-line regimens. In addition, the development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The result has been the availability of several molecular-targeted therapies demonstrating some degree of activity in subsets of NSCLC.

    These advances present new promise of both efficacy and enhanced safety for patients with lung cancer but also challenge practicing oncologists to appropriately select individuals who may benefit from these strategies. This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations, Q&A and discussion of community practice patterns to assist practicing clinicians in making informed and individualized patient care decisions.


    • Effectively utilize validated biomarkers to tailor NSCLC treatment recommendations.
    • Counsel patients with squamous and nonsquamous lung cancer about the efficacy and safety of diverse chemotherapeutic and biologic systemic interventions.
    • Apply the results of emerging clinical and translational research — including data sets presented at ASCO 2011 — to the current and future care of patients with NSCLC.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Lucian R Chirieac, MD
    Associate Professor of Pathology
    Harvard Medical School
    Pathologist, Brigham and Women's Hospital
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    Thomas J Lynch Jr, MD
    Jonathan and Richard Sackler Professor of Internal Medicine
    Director, Yale Cancer Center
    Physician-in-Chief, Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut

    Board of Directors: Infinity Pharmaceuticals Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, SuperGen Inc; Stock Ownership: Biogen Idec, Infinity Pharmaceuticals Inc.

    Lecia V Sequist, MD, MPH
    Assistant Professor of Medicine, Harvard Medical School
    Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee: GlaxoSmithKline; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech BioOncology, Lilly USA LLC, Merrimack Pharmaceuticals.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Genentech BioOncology & OSI Oncology and Lilly USA LLC.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2011
    Expiration date: July 2012

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):